First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

BACKGROUND: OX40 is a costimulatory receptor upregulated on antigen-activated T cells and constitutively expressed on regulatory T cells (Tregs). INCAGN01949, a fully human immunoglobulin G1κ anti-OX40 agonist monoclonal antibody, was designed to promote tumor-specific immunity by effector T-cell ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Elizabeth J, Martin-Liberal, Juan, Kristeleit, Rebecca, Cho, Daniel C, Blagden, Sarah P, Berthold, Dominik, Cardin, Dana B, Vieito, Maria, Miller, Rowan E, Hari Dass, Prashanth, Orcurto, Angela, Spencer, Kristen, Janik, John E, Clark, Jason, Condamine, Thomas, Pulini, Jennifer, Chen, Xuejun, Mehnert, Janice M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628691/
https://www.ncbi.nlm.nih.gov/pubmed/36316061
http://dx.doi.org/10.1136/jitc-2021-004235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628691/
https://www.ncbi.nlm.nih.gov/pubmed/36316061
http://dx.doi.org/10.1136/jitc-2021-004235

Ejemplares similares